Mitigating and learning from the impact of COVID-19 infection on addictive disorders - PubMed (original) (raw)
Editorial
. 2020 Jun;115(6):1007-1010.
doi: 10.1111/add.15080. Epub 2020 Apr 28.
Affiliations
- PMID: 32250482
- PMCID: PMC9364227
- DOI: 10.1111/add.15080
Editorial
Mitigating and learning from the impact of COVID-19 infection on addictive disorders
John Marsden et al. Addiction. 2020 Jun.
Abstract
The COVID-19 pandemic and the measures required to address it are cutting a swathe through people’s lives and the global economy. People with addictive disorders are particularly badly affected as a result of poverty, physical and mental health vulnerabilities and disruption of access to services. The pandemic may well increase the extent and severity of some addictive disorders. Current research is suffering from the termination of face-to-face data collection and other restrictions. There is an urgent need to coordinate efforts nationally and internationally to mitigate these problems and to find innovative ways of continuing to provide clinical and public health services to help people with addictive disorders.
Keywords: Addictive disorders; COVID-19; public health; public health policy; research; treatment.
Comment in
- Response to Marsden et al (2020): Mitigation for the impacts on needle and syringe programmes is needed.
Whitfield M, Reed H, Webster J, Hope V. Whitfield M, et al. Addiction. 2021 Jan;116(1):206-207. doi: 10.1111/add.15193. Epub 2020 Aug 11. Addiction. 2021. PMID: 32696539 No abstract available.
Similar articles
- New Challenges in Addiction Medicine: COVID-19 Infection in Patients With Alcohol and Substance Use Disorders-The Perfect Storm.
Spagnolo PA, Montemitro C, Leggio L. Spagnolo PA, et al. Am J Psychiatry. 2020 Sep 1;177(9):805-807. doi: 10.1176/appi.ajp.2020.20040417. Epub 2020 Jul 14. Am J Psychiatry. 2020. PMID: 32660296 Free PMC article. No abstract available. - [Transmural addiction care in times of COVID-19 outbreak].
de Cauwer H, Leenders J, Vloemans P, Mondelaers R, Viaene M. de Cauwer H, et al. Tijdschr Psychiatr. 2020;62(5):329-331. Tijdschr Psychiatr. 2020. PMID: 32902834 Dutch. No abstract available. - Mental health and COVID-19: change the conversation.
The Lancet Psychiatry. The Lancet Psychiatry. Lancet Psychiatry. 2020 Jun;7(6):463. doi: 10.1016/S2215-0366(20)30194-2. Epub 2020 May 4. Lancet Psychiatry. 2020. PMID: 32380007 Free PMC article. No abstract available. - Addiction as a Coping Response: Hyperkatifeia, Deaths of Despair, and COVID-19.
Koob GF, Powell P, White A. Koob GF, et al. Am J Psychiatry. 2020 Nov 1;177(11):1031-1037. doi: 10.1176/appi.ajp.2020.20091375. Am J Psychiatry. 2020. PMID: 33135468 Review. No abstract available. - COVID-19 and addiction.
Dubey MJ, Ghosh R, Chatterjee S, Biswas P, Chatterjee S, Dubey S. Dubey MJ, et al. Diabetes Metab Syndr. 2020 Sep-Oct;14(5):817-823. doi: 10.1016/j.dsx.2020.06.008. Epub 2020 Jun 9. Diabetes Metab Syndr. 2020. PMID: 32540735 Free PMC article. Review.
Cited by
- Seroprevalence of SARS-CoV-2 and humoral immune responses to COVID-19 mRNA vaccines among people who use drugs - in the light of tailored mitigating strategies.
Wüsthoff LEC, Lund-Johansen F, Henriksen K, Wildendahl G, Jacobsen JA, Gomes L, Anjum HS, Barlinn R, Kran AB, Munthe LA, Vaage JT. Wüsthoff LEC, et al. Harm Reduct J. 2024 Jun 19;21(1):120. doi: 10.1186/s12954-024-01023-9. Harm Reduct J. 2024. PMID: 38890611 Free PMC article. - People who use drugs show no increase in pre-existing T-cell cross-reactivity toward SARS-CoV-2 but develop a normal polyfunctional T-cell response after standard mRNA vaccination.
Gainullin M, Federico L, Røkke Osen J, Chaban V, Kared H, Alirezaylavasani A, Lund-Johansen F, Wildendahl G, Jacobsen JA, Sarwar Anjum H, Stratford R, Tennøe S, Malone B, Clancy T, Vaage JT, Henriksen K, Wüsthoff L, Munthe LA. Gainullin M, et al. Front Immunol. 2024 Jan 17;14:1235210. doi: 10.3389/fimmu.2023.1235210. eCollection 2023. Front Immunol. 2024. PMID: 38299149 Free PMC article. - Understanding and learning from rural drug service adaptations to opioid substitution therapy during the COVID-19 pandemic: the What C-OST? study.
Scott J, Family H, Kesten JM, Hines L, Millar J. Scott J, et al. Front Public Health. 2023 Nov 30;11:1240402. doi: 10.3389/fpubh.2023.1240402. eCollection 2023. Front Public Health. 2023. PMID: 38098825 Free PMC article. - Relieving the Gambling Itch Through Alcohol Consumption: The Impact of COVID-19 Restrictions on Australian Casino Patrons.
Zhang T, Seet PS, Redmond J, Sharafizad J. Zhang T, et al. J Gambl Stud. 2023 Dec;39(4):1675-1697. doi: 10.1007/s10899-023-10252-9. Epub 2023 Sep 27. J Gambl Stud. 2023. PMID: 37755624 Free PMC article.
References
- Hedegaard H, Warner M, Minino AM. Drug overdose deaths in the United States, 1999–2016. CHS Data Brief, no. 294. Hyattsville, MD: National Center for Health Statistics, 2017; Centers for Disease Control and Prevention. National Vital Statistics System, Mortality; CDC Wonder. Atlanta, GA: US Department of Health and Human Services, CDC; 2017.
- European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2017: Trends and Developments. Luxembourg: Office of the European Union, 2017. Available at: http://www.emcdda.europa.eu/publications/edr/trendsdevelopments/2017 (accessed 4 April 2020).
- Advisory Council on the Misuse of Drugs. Drug-related harms in homeless populations and how they can be reduced. London; 2019. Available at: https://assets.publishing.service.gov.uk/government/uploads/system/uploa... (accessed 4 April 2020).
Publication types
MeSH terms
Grants and funding
- R01 AA022328/AA/NIAAA NIH HHS/United States
- R01 AA023657/AA/NIAAA NIH HHS/United States
- R01 AA024930/AA/NIAAA NIH HHS/United States
- UL1 TR001427/TR/NCATS NIH HHS/United States